Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 문영철 | * |
dc.date.accessioned | 2019-12-03T16:30:19Z | - |
dc.date.available | 2019-12-03T16:30:19Z | - |
dc.date.issued | 2019 | * |
dc.identifier.issn | 2152-2650 | * |
dc.identifier.issn | 2152-2669 | * |
dc.identifier.other | OAK-26054 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/252287 | - |
dc.description.abstract | Decitabine showed a survival benefit in the higher-risk group (Lower-Risk Prognostic Scoring System [LR-PSS] category 3) of the International Prognostic Scoring System (IPSS) lower-risk (IPSS low or intermediate-1) myelodysplastic syndrome patients who responded to decitabine. Therefore, classification using the LR-PSS category was helpful for this subgroup, indicating that decitabine treatment might alter the natural course of disease in these patients. Introduction: Decitabine has shown clinical benefits in patients with intermediate (INT)-2 or high-risk myelodysplastic syndrome (MDS), determined according to the International Prognostic Scoring System (IPSS), but the benefits have not been well demonstrated in patients with lower-risk (IPSS low or INT-1) disease. Recently, it was proposed that the prognosis for patients with IPSS lower-risk disease is heterogeneous, with a substantial proportion of these patients having poor survival. Patients and Methods: This study included patients with IPSS lower-risk MDS from the DRAMA (An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome; NCT01400633) and DIVA (A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome; NCT01041846) studies, which were prospective observational studies on the efficacy and safety of decitabine treatment in patients with MDS. Using the Lower-Risk Prognostic Scoring System [LR-PSS], we classified IPSS lower-risk MDS. Patients in each LR-PSS category were divided according to overall response (OR) to decitabine treatment, and survival outcomes were compared. Results: One hundred sixteen patients were enrolled: LR-PSS category 1 (n = 12; 10.3%), category 2 (n = 56; 48.3%), and category 3 (n = 48; 41.4%). Survival outcomes differed among the 3 categories (P = .046). The overall survival according to OR showed a significant difference in total patients (P = .008) and category 3 patients (P = .003). We analyzed predictive factors for OR, but no variable was found to significantly affect OR. Conclusion: Decitabine treatment showed a survival benefit in the higher-risk group of IPSS lower-risk MDS patients who responded to treatment, and classification using the LR-PSS category was helpful for this subgroup, indicating that decitabine treatment might alter the natural course of disease in these patients. | * |
dc.language | English | * |
dc.publisher | CIG MEDIA GROUP, LP | * |
dc.subject | Decitabine | * |
dc.subject | IPSS | * |
dc.subject | Lower-Risk Prognostic Scoring System | * |
dc.subject | LR-PSS | * |
dc.subject | Myelodysplastic syndrome | * |
dc.title | Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System | * |
dc.type | Article | * |
dc.relation.issue | 10 | * |
dc.relation.volume | 19 | * |
dc.relation.index | SCIE | * |
dc.relation.startpage | 656 | * |
dc.relation.lastpage | 664 | * |
dc.relation.journaltitle | CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | * |
dc.identifier.doi | 10.1016/j.clml.2019.06.003 | * |
dc.identifier.wosid | WOS:000493990400012 | * |
dc.author.google | Jung, Ki Sun | * |
dc.author.google | Kim, Yoo-Jin | * |
dc.author.google | Kim, Yeo-Kyeoung | * |
dc.author.google | Park, Sung Kyu | * |
dc.author.google | Kim, Hoon Gu | * |
dc.author.google | Kim, Soo Jeong | * |
dc.author.google | Park, Jinny | * |
dc.author.google | Choi, Chul Won | * |
dc.author.google | Do, Young Rok | * |
dc.author.google | Kim, Inho | * |
dc.author.google | Park, Seonyang | * |
dc.author.google | Mun, Yeung-Chul | * |
dc.author.google | Jeong, Seong Hyun | * |
dc.author.google | Kim, Min-Kyoung | * |
dc.author.google | Yi, Hyeon Gyu | * |
dc.author.google | Chang, Myung Hee | * |
dc.author.google | Kim, Su Youn | * |
dc.author.google | Lee, Je-Hwan | * |
dc.author.google | Jang, Jun Ho | * |
dc.contributor.scopusid | 문영철(7003363716) | * |
dc.date.modifydate | 20240422115947 | * |